Pancreatic cancer remains one of the deadliest malignancies worldwide. Since five-year survival rate for pancreatic ductal adenocarcinoma (PDAC) is only about 3% in patients, PDAC is very difficult to treat with surgery worldwide. ...
Dec 15, 2022
0
31
A patient's own immune cells, multiplied into an army of billions of immune cells in a lab, can be used as a living medicine against metastatic melanoma, an aggressive form of skin cancer, as the TIL trial has shown. The ...
Dec 8, 2022
0
3
Second-line treatment with trastuzumab deruxtecan (T-DXd) led to significantly longer overall survival compared with trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer, according to updated ...
Dec 7, 2022
0
23
The notorious spike protein of SARS-CoV-2, the virus that causes COVID-19, caused lung cancer cells to die in laboratory studies conducted by researchers at RUSH University Medical Center, who recently published their findings ...
Dec 6, 2022
0
154
Immunotherapy is a cutting-edge approach to treating cancer by turning the patient's own immune system against their tumor. Our increasing knowledge of the mechanisms by which the body regulates immune responses has been ...
Nov 17, 2022
0
32
Researchers at the University of Michigan Rogel Cancer Center have identified a novel treatment approach to an aggressive type of pediatric brain cancer, using therapies already approved to treat cancer.
Nov 15, 2022
0
23
Social determinants of health affect the outcomes of many illnesses, and pediatric cancer is no exception. In fact, children with acute lymphoblastic leukemia (ALL) living in poverty are significantly more likely to relapse ...
Nov 10, 2022
0
2
A new approach to stem cell therapy that uses antibodies instead of traditional immunosuppressant drugs robustly preserves cells in mouse brains and has potential to fast-track trials in humans, a Michigan Medicine study ...
Nov 9, 2022
0
19
The Phase II results of the NRG Oncology HN004 trial indicate that radiotherapy (RT) with the PD-L1 inhibitor durvalumab did not improve progression-free survival (PFS) and led to significantly higher rates of locoregional ...
Oct 24, 2022
0
6
A global study into mucinous ovarian cancer could help oncologists recommend the best treatment for women who are diagnosed early with the condition.
Oct 12, 2022
0
10
